Prodigy gastric cancer
Webb1 juni 2024 · 4007 Background: Although postoperative adjuvant chemotherapy with S-1 is among the standard treatments for curatively resected pStage II/III gastric cancer (GC) in Asia, the outcome of pStage III GC remains unsatisfactory. Postoperative S-1/docetaxel had been among candidates for the new standard treatment. Methods: JACCRO GC-7, a … Webb9 sep. 2024 · PRODIGY was a phase III, open-label, randomized study of neoadjuvant DOS followed by surgery plus adjuvant S-1 versus surgery followed by adjuvant S-1 in patients with resectable advanced gastric cancer (Appendix Fig A A1, 1, online only).
Prodigy gastric cancer
Did you know?
Webb11 apr. 2024 · Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally … Webb16 juni 2024 · PRODIGY was a phase III, open-label, randomized study of neoadjuvant DOS followed by surgery plus adjuvant S-1 versus surgery followed by adjuvant S-1 in …
Webb20 maj 2015 · TPS4136 Background: Although adjuvant chemotherapy with S-1 is now considered a standard after D2 resection in stage II or III locally advanced gastric cancer (LAGC) in Asia, many patients still experience recurrence of disease. Addition of neoadjuvant chemotherapy can be one method to further improve outcomes in LAGC. A … Webb25 maj 2024 · Background: PRODIGE 23 investigated the role of neoadjuvant mFOLFIRINOX before preoperative (preop) chemoradiation (CRT), with TME-surgery and adjuvant …
Webb22 apr. 2024 · An estimated 1.1 million new cases of gastric cancer and 770 000 deaths caused by gastric cancer occurred in 2024, with incidence rates being on average twice as high in males as in females. Men residing in eastern Asian countries such as Japan, Mongolia, and the Republic of Korea had the highest incidence rates in the world, while …
Webb2 dec. 2024 · Adjuvant chemotherapy and chemoradiotherapy are some of the standards of care for gastric cancer (GC). The Adjuvant chemoRadioTherapy In Stomach Tumors (ARTIST) 2 trial compares two adjuvant chemotherapy regimens and chemoradiotherapy in patients with D2-resected, stage II or III, node-positive GC.
Webb23 juli 2024 · After starting OGSG1902, the PRODIGY study, a phase III trial of neoadjuvant DOS plus surgery and adjuvant S-1 versus surgery and adjuvant S-1 for gastric cancer of T2-3N+ or T4Nany, showed that PFS was significantly superior in the neoadjuvant DOS arm (HR for PFS adjusted for stratification factors: 0.70, 95% CI: 0.52–0.95, stratified log-rank … journal of money credit and banking怎么样WebbDeterminants of clinical outcomes of gastric cancer patients treated with neoadjuvant chemotherapy: a sub-analysis of the PRODIGY study Determinants of clinical outcomes of gastric cancer patients treated with neoadjuvant chemotherapy: a sub-analysis of the PRODIGY study Authors journal of molecular 影响因子WebbWhen they happen, symptoms might include indigestion and pain in the upper part of the belly. Symptoms might not happen until the cancer is advanced. Later stages of stomach cancer might cause symptoms such … journal of molluscan studies impact factorWebbIn this exploratory analysis from the PRODIGY study, we aimed to define the radiological criteria to identify patients with gastric cancer who may derive maximal clinical benefit from neoadjuvant chemotherapy. Methods. There were 246 patients allocated to receive surgery followed by adjuvant S-1 ... journal of money investment and bankingWebbBackground: In this post hoc analysis of the PRODIGY study, we aimed to investigate factors associated with survival outcomes and provide evidence for designing optimal … how to maintain discipline in schoolWebbNeoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial Institut National du Cancer, Ligue Nationale Contre le Cancer, and R&D Unicancer. how to maintain discipline at homeWebb7 apr. 2024 · Background: Gastric cancer (GC) is one of the most common malignant cancers worldwide. The development of potential antitumor agents is being investigated and stimulates more clinical trials. Overall survival (OS) is consistently considered the primary endpoint for clinical trials on treatment effect assessment. how to maintain dining table